Optimising drug discovery and development to advance research and education

Sim Yi Jin Gladys
Senior Assistant Manager

The Drug Discovery and Optimization Platform (DDOP) under Department of Pharmacology, NUS Yong Loo Lin School of Medicine, hosts the Milliplex® technology via the Magpix® in the laboratory at the Department of Pharmacology.

Group photo between the parties from Merck and NUS Medicine involved in this event

Where DDOP has goals to reach out to the generation of young scientists and seasoned researchers regarding this technology, Merck, a commercial company as well as the producer of the kits used to run on the Magpix®, there is a common goal to bring the Milliplex® technology to the scientific and academic community.

"The initiative of this partnership between DDOP and Merck is a natural development because DDOP has been using the Milliplex^{Ò} system to perform drug screening and biomarker identification," said Professor Wai-Shiu Fred Wong, Director of DDOP, from NUS Medicine Department of Pharmacology.

Opening speech by Prof Wai-Shiu Fred Wong, Director and PI of the Drug Discovery and Optimization Platform (DDOP)

With the combination of academia, scientific research and commercial technology offered by NUS and Merck, the 'Milliplex® Assays Discovery and Education Partnership' was formed officially on 31 March 2022. "The aim of this DDOP-Merck collaboration is not only for discovery research support but also for education advancement," added Prof Wong.

The inauguration ceremony held on 19 July 2022 officially celebrates the start of this new exciting partnership. This initiative is supported by Merck, represented by Mr Alex Zong, the Head of Singapore & Malaysia, Science and Lab Solutions, as well as NUS Medicine, represented by Vice-Dean (Research), Professor Chng Wee Joo. Both parties are the VIPs and signatories officiating the MOU signing ceremony.

Closing speech by Prof Chng Wee Joo